Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : N::A tags : Pharma save search
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-15 (Crawled : 16:00) - biospace.com/
BETR | $0.4318 -4.13% -4.31% 680K
|
n/a
|
| O: -1.21%
H: 1.36%
C: -4.41%
BETRF | $0.0721 -3.71% 15K
|
Health Technology
|
| O: -8.49%
H: 11.31%
C: 11.31%
pharma conference
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: 1.87%
H: 4.59%
C: -3.67%
pharma disease alzheimer’s acquire spc-14
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -6.3%
H: 2.72%
C: -2.67%
pharma disease global trial cardiovascular
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: 6.23%
H: 2.77%
C: -10.21%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.23%
C: -0.99%
pharma business
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -1.03%
H: 2.61%
C: 1.91%
pharma congress trial cardiology
Nutra Pharma Corp. Reaches Settlement with SEC
Published: 2024-03-22 (Crawled : 21:00) - globenewswire.com
NPHC | $0.0001 2900.0% 3
|
Manufacturing
| Email alert
Add to watchlist
MEDE | News | $0.51 0% 500
|
n/a
| Email alert
Add to watchlist
pharma
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
Published: 2024-03-20 (Crawled : 12:30) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: 1.14%
H: 2.26%
C: 2.26%
pharma license agreement
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: -6.52%
H: 9.88%
C: 4.07%
ketamine pharma patent fibromyalgia implant
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -0.14%
H: 14.78%
C: 12.05%
first pharma trial
Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $172.54 -19.21% 50
|
n/a
|
| O: 0.41%
H: 0.0%
C: 0.0%
CSLLY | $86.918 3.3% 60K
|
n/a
|
| O: -4.92%
H: 3.76%
C: 3.44%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.4%
H: 1.49%
C: 1.49%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.6%
H: 0.19%
C: 0.09%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
pharma vaccine astrazeneca research key market
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-02-28 (Crawled : 13:30) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -1.16%
H: 4.01%
C: -1.38%
pharma year update financial results
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
Published: 2024-02-28 (Crawled : 13:30) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: 10.32%
H: 3.51%
C: -5.26%
spc-15 pharma study spc-14
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: 0.22%
H: 2.16%
C: -4.87%
pharma
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Published: 2024-02-14 (Crawled : 04:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -3.0%
H: 3.92%
C: 3.35%
pharma million offering
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Published: 2024-02-13 (Crawled : 21:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -3.0%
H: 3.92%
C: 3.35%
pharma offering
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-02-01 (Crawled : 21:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -1.44%
H: 3.71%
C: -4.63%
pharma conference
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
Published: 2024-02-01 (Crawled : 15:00) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: -2.58%
H: 3.97%
C: 3.97%
pharma pipeline
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
Published: 2024-01-24 (Crawled : 14:00) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: 10.0%
H: 5.19%
C: -3.9%
pharma disease alzheimer’s positive results study
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
SXTP | $0.245 -0.57% -0.57% 92K
|
n/a
|
| O: 5.11%
H: 35.11%
C: 14.13%
fda pharma meeting study
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
SXTP | $0.245 -0.57% -0.57% 92K
|
n/a
|
| O: 1.12%
H: 2.41%
C: -0.08%
pharma nasdaq
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.